Retractable Technologies, Inc. (ARCA:RVP) insider have most recently took part in a trading activity. On Dec 15, 2017 Shaw Thomas J, President and CEO, 10% Owner bought 5,715 shares having total worth of $3,772 at the price of $0.66 per share, following the transaction a total of 17,532,771 shares owned by Shaw Thomas J. Before this latest buy, Shaw Thomas J purchased RVP at 26 other times during the past twelve months, for a total investment of $24.79M at an average of $0.64 per share.
The stock has experienced a total of 24 insider trades in the past three months. These trades include 24 buy trades. Furthermore, over the past 12 months , the stock was traded 26 times by insiders. an employee of the company was the buyer in 26 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Retractable Technologies, Inc. (ARCA:RVP) traded down 9.09% on Dec 15, 2017, hitting $0.67. 383,935 shares of the company’s stock traded hands. Retractable Technologies, Inc. has a 52 week low of $0.57 and a 52 week high of $2.75. The company’s market cap is $77 million.
Retractable Technologies, Inc. was incorporated in Texas on May 9, 1994. The Company designs, develops, manufactures, and markets innovative patented safety medical products for the healthcare industry. The Company’s products with Notice of Substantial Equivalence to the U.S. Food and Drug Administration (FDA) and which are currently sold include the 1mL tuberculin; insulin; allergy antigen VanishPoint syringes; 3mL, 5mL, and 10mL VanishPoint syringes; the VanishPoint blood collection tube holder; the VanishPoint IV safety catheter; small diameter tube adapter; the Patient Safe syringe; the Patient Safe Luer Cap; and the VanishPoint Blood Collection Set. It is also selling autodisable syringes in the international market. The Company’s VanishPoint safety products (consisting of 1mL tuberculin, insulin, and allergy antigen VanishPoint syringes; 0.5mL, 3mL, 5mL, and 10mL VanishPoint syringes; the VanishPoint blood collection tube holder; autodisable syringe; the VanishPoint IV safety catheter; and the VanishPoint Blood Collection Set) utilize a unique friction ring mechanism. The friction ring mechanism permits the automated retraction of the syringe needle into the barrel of the syringe, directly from the patient, after delivery of the medication is completed. The VanishPoint blood collection tube holder utilizes the same mechanism to retract the needle after blood has been drawn from the patient. Closure of an attached end cap of the blood collection tube holder causes the needle to retract directly from the patient into the closed blood collection tube holder. The IV catheter also operates with a friction ring mechanism whereby the needle is retracted after insertion of the catheter into the patient. It also has a Patient Safe syringe which reduces the risk of infection resulting from IV line contamination. Advantages of its VanishPoint safety needle products include protection from needlestick injuries, prevention of cross contamination through reuse, and reduction of disposal and other associated costs. Federal regulation now requires the use of safe needle devices. The Company distributes its products throughout the U.S. and its territories through general line and specialty distributors. It also has trademark protection for the phrase ‘The New Standard for Safety’.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018